Canada: Federal Court Of Appeal Grants Minister Of Health The Right To Be Wrong

In a decision1 dated October 12, 2016, the Federal Court of Appeal upheld two decisions of the minister of health (the "minister") to issue Notice of Compliances ("NOCs") to generic drug manufacturers without addressing the requirements of the Patented Medicines (Notice of Compliance) Regulations (the "NOC Regulations"). Importantly, the Court of Appeal held that the minister's decisions were to be reviewed on a standard of reasonableness, unlike prior Supreme Court jurisprudence, which had applied a correctness standard to the minister. The Court of Appeal found both of the minister's decisions to be reasonable, overturning the Federal Court's finding that they were incorrect, and effectively granting the minister the right to be wrong.

Background of the cases: the two drug submissions at issue

This appeal involved two different NOCs for different products. The first NOC was obtained by Teva Canada for a generic version of the AROMASIN product marketed by Pfizer Canada. Teva had filed an abbreviated new drug submission ("ANDS") without any data establishing bioequivalence between its generic product and AROMASIN. Instead, Teva included a certification that its drug product was identical in all respects to a previously-approved generic version of AROMASIN. Teva did not serve a Notice of Allegation on Pfizer to address the patents listed on the Patent Register against AROMASIN. Nevertheless, the minister issued an NOC to Teva.

A second NOC was issued to Hospira Healthcare Corporation ("Hospira") for its generic version of the REMICADE product marketed by Janssen Inc. ("Janssen"). Unlike AROMASIN, REMICADE is a biologic. Generic versions of biologics are approved by filing an NDS demonstrating similarity to the reference biologic drug, rather than by filing an ANDS. Hospira's NDS however did not contain any data. Hospira instead certified that it had entered into a license agreement to take over the marketing of a previously-approved generic REMICADE product. The previous generic manufacturer would no longer market the drug. Hospira did not issue a NOA to Janssen to address the patents listed against REMICADE, yet still received an NOC.

Pfizer and Janssen filed separate judicial review applications relating to the minister's decisions to issue NOCs without addressing the listed patents listed against their respective drugs.

The underlying Federal Court decisions

Pfizer's application was heard and decided first.2 The Federal Court found that the minister's decision to issue an NOC to Teva was incorrect. In determining the standard of review was correctness, the Federal Court started with the presumption that the standard is reasonableness, but found that presumption rebutted based on a contextual analysis of the case. In particular, the Federal Court found that the NOC Regulations do not afford the minister any discretion as to when to issue an NOC. Rather, that decision is mandated by the NOC Regulations and is left to the Courts during prohibition applications under those regulations. Both Teva and the minister appealed this decision, and the appeals were later consolidated.

The Federal Court's decision was released while Janssen's judicial review application remained pending. The Federal Court, on consent of the parties, set aside the decision of the minister to issue the NOC to Hospira, without prejudice to any right of appeal. Hospira and the minister appealed the judgment, and these appeals were consolidated with those in the case involving Pfizer.

Shift to a deferential standard of review

The standard of review was the critical issue before the Federal Court of Appeal. Indeed, the Federal Court had commented that the "[s]election of the appropriate standard of review in this case determines the outcome as [...] there is more than one reasonable interpretation of the NOC Regulations. However, there is only one correct interpretation."

The Federal Court of Appeal began by discounting prior jurisprudence applying a standard of correctness to decisions of the minister. The Court found, for example, that two Supreme Court decisions applying this standard to decisions of the minister made under the NOC Regulations in similar factual circumstances3 were not binding because they were decided without regard to the presumption of reasonableness later articulated by the Supreme Court. The Court of Appeal found no applicable binding jurisprudence on the standard of review and thus found that the accepted presumption of reasonableness applied.

The Court of Appeal added that the presumption arises when the administrative decision-maker is interpreting both its home statute and statutes closely connected to its function. In the Court of Appeal's view, the NOC Regulations are closely connected to the minister's function.

The Court of Appeal then disagreed with the Federal Court's conclusion that the presumption was rebutted. First, the Court of Appeal found that the NOC Regulations do not suggest that Parliament intended the minister's interpretation of the NOC Regulations be reviewed on a less deferential standard.

Next, the Court of Appeal disagreed with the Federal Court that the decision to issue an NOC is left to the Courts. The Court held that the minister has exclusive jurisdiction to determine whether a drug submission makes a direct or indirect comparison to a Canadian reference product such that the generic drug manufacturer must address any listed patents. The Courts are, the finding goes, only involved if the minister decides in its discretion that a direct or indirect comparison has been made.  They do not, the Court of Appeal found, decide during prohibition applications under the NOC Regulations whether the minister ought to have subjected the generic submission to those regulations at all.

The Court of Appeal also found, without further explanation, that the question at issue was one of mixed fact and law, and thus the reasonableness standard applied.

For these reasons, the Court of Appeal found that the deferential standard of reasonableness applied. The Court ultimately found that the minister's decision was reasonable, as the Federal Court had acknowledged. The minister's decisions were therefore reinstated such that the NOCs granted to Teva and Hospira were upheld.

Future implications

These appeals follow a recent juridical trend away from the consideration of whether decisions made by the minister of health are correct. For example, after years of consistently applying the correctness standard in judicial review applications involving data protection (with the minister accepting this standard in most cases4), the Federal Court recently accepted the minister's argument that the reasonableness standard ought to apply.5 This trend is also apparent in other analogous contexts. For example, the Supreme Court recently questioned the Patented Medicines Price Review Board's acceptance of the correctness standard.6 Subsequently, in a different case, the Court of Appeal accepted the Board's argument that the reasonableness standard applied.7

In the high-stakes world of pharmaceutical disputes, a reasonableness standard of review can have profound consequences for drug manufacturers. In the appeals discussed above, two innovative drug companies lost the opportunity to resist generic market entry under the NOC Regulations as a result of the application of the standard of review of reasonableness. This occurred despite the Federal Court's finding that the minister's decision was incorrect. The Court of Appeal's comment that those manufacturers retain the ability to sue for patent infringement may provide little comfort given the significant, and often immediate, impact of generic market entry and the well-known obstacles to obtaining interlocutory injunctions. Similar concerns apply in other regulatory niches, such as in the data protection context, where the minister decides whether an innovative drug manufacturer ought to be granted eight years of data exclusivity for an innovative drug. The minister may now be able to simply elect between various reasonable outcomes, leaving aside the previous, necessary rigour of achieving the correct outcome.


1 Teva Canada Limited v Pfizer Canada Inc., 2016 FCA 248.

2 Pfizer Canada Inc. v Canada (Health), 2014 FC 1243.

3Bristol-Myers Squibb Co. v Canada (Attorney General), 2005 SCC 26; AstraZeneca v Canada (minister of health), 2006 SCC 49.

4 See for example Takeda Canada Inc. v Canada (minister of health), 2013 FCA 13.

5 Photocure ASA v Canada (Health), 2015 FC 959.

6 Celgene Corp v. Canada (Attorney General), 2011 SCC 1.

7 Canada (Attorney General) v Sandoz Canada Inc, 2015 FCA 249.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
14 Sep 2017, Seminar, Birmingham, UK

Has Cloud replaced traditional outsourcing models? We will compare cloud to outsourcing, consider whether they have effectively become the same thing for many solutions and assess some of the advantages and disadvantages of each model.

18 Sep 2017, Seminar, London, UK

Our annual event as part of the London Design Festival is now in its fifth year. We would be delighted if you are able to join us again.

21 Sep 2017, Seminar, London, UK

Has Cloud replaced traditional outsourcing models? We will compare cloud to outsourcing, consider whether they have effectively become the same thing for many solutions and assess some of the advantages and disadvantages of each model.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.